Arcus Biosciences, Inc.
https://www.arcusbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Arcus Biosciences, Inc.
Gilead Made Gains In Oncology, Though Virology Remains King
Pipeline-in-a-product approaches have become popular in biopharma, and Gilead has been making significant strides.
Finance Watch: Argenx Raises $1.15bn For Efgartigimod Commercialization
Public Company Edition: Among other recent large financings, BridgeBio Pharma launched a $650m note sale, CureVac closed a $517.5m follow-on offering and Revolution Medicines raised $260.9m.
ESMO: Merck & Co Vibostolimab Data Are Another Validation Of TIGIT
A number of anti-TIGIT drugs are jockeying for position to provide benefit as monotherapies and in combinations for non-small cell lung cancer and Merck's offering is looking to challenge Roche's tiragolumab for the lead.
Gilead’s Immunomedics Buy: Five Things To Worry About
Acquisition is based on the prospects for Immunomedics’ Trodelvy, but regulatory changes, manufacturing challenges, and research dynamics could upset even the best-laid plans.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule